Cambridge – September 07, 2026 -- Insilico Medicine (HKEX: 3696) will join the HKEX Tech 100 Index effective September 14, 2026, following methodology changes announced August 18, 2026, that widen the benchmark's exposure to the AI value chain. Index changes take effect after market close on September 11, 2026 (Friday).
HKEX Tech 100 Index tracks 100 leading Hong Kong tech names across six themes
The index measures 100 of the largest Hong Kong-listed companies with high exposure to technology themes eligible for Southbound Stock Connect. It spans artificial intelligence, biotech and pharmaceutical, electric vehicles and smart driving, information technology, internet, and robotics.
Inclusion links Insilico directly to Mainland Chinese capital flows
Because the index feeds into Southbound Stock Connect, Insilico's addition is expected to draw inflows from index-tracking passive funds and Mainland Chinese investors, broadening its shareholder base and lifting trading liquidity. The company has previously entered MSCI Global Small Cap Indexes, the CSI Hong Kong Connect Innovative Drug Index, CSI Hong Kong Brand Name Drug Index, CSI HK Connect Health Care Composite Index, Hang Seng Composite Index, Hang Seng Healthcare Index, Hang Seng Biotechnology Index, and FTSE Global Small Cap, All-Cap, and Total-Cap Indexes.
First-half 2026 revenue hits $106 million, up 287% year-over-year
Insilico posted adjusted net profit exceeding $51 million in H1 2026, its first profitable half since listing on December 30, 2025. Growth was driven by out-licensing, co-development, and R&D partnerships with Eli Lilly, Servier, Takeda, SK Biopharmaceuticals, Qilu Pharmaceutical, Hygtia Therapeutics, CMS, and Tenacia. Total contract value of transactions announced in 2026 reached approximately $7.3 billion, pushing cumulative collaboration value since 2021 to roughly $11 billion.
Pipeline sets annual record with nine development candidates in nine months
As of late August 2026, Insilico nominated nine development candidates and hit eight clinical milestones across proprietary and co-developed programs. Rentosertib (ISM001-055), described as the world's first drug candidate discovered and developed using generative AI, has advanced to a Phase III trial for idiopathic pulmonary fibrosis.